Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $40.94: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: High short interest: 15%; Elevated put/call ratio: 17.17; Below-average business quality.
Apellis Pharmaceuticals is a commercial-stage biopharma with two marketed complement inhibitors: SYFOVRE for geographic atrophy ($586.9M US net revenue 2025) and EMPAVELI for PNH/C3G/IC-MPGN ($102.4M US net revenue). Ex-U.S. commercialization of EMPAVELI is handled by Sobi. In... Read more
Sell if holding. Engine safety override at $40.94: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: High short interest: 15%; Elevated put/call ratio: 17.17; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 3.7/10, high confidence.
Passes 5/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductSYFOVRE10-K Item 1A: 'Our prospects depend substantially upon the commercial success of SYFOVRE.'
Material Events(8-K, last 90d)
- 2026-03-31Item 1.01HIGHApellis entered Agreement and Plan of Merger with Biogen Inc. Offer: $41.00/share cash plus one CVR worth up to $4.00 on milestone achievement. Tender offer to commence within 20 business days. Change of control transaction.SEC filing →
- 2026-03-02Item 5.02LOWBoard elected Mikael Dolsten, M.D., Ph.D. as Class I director effective March 1, 2026, to serve until 2027 Annual Meeting. Determined independent under Nasdaq rules. No committee appointment cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Revenue shrinking — -5.9% YoY. Growth thesis broken unless recovery story develops.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $40.94: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: High short interest: 15%; Elevated put/call ratio: 17.17; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $40.80. Score 3.7/10, high confidence.
Take-profit target: $40.18 (-1.9% upside). Prior stop was $40.80. Stop-loss: $40.80.
Concentration risk — Product: SYFOVRE; Target reached (-10.0% upside); Quality below floor (4.0 < 4.0).
Apellis Pharmaceuticals, Inc. trades at a P/E of 227.5 (forward -167.7). TrendMatrix value score: 4.5/10. Verdict: Sell.
27 analysts cover APLS with a consensus score of 3.6/5. Average price target: $41.
What does Apellis Pharmaceuticals, Inc. do?Apellis Pharmaceuticals is a commercial-stage biopharma with two marketed complement inhibitors: SYFOVRE for geographic...
Apellis Pharmaceuticals is a commercial-stage biopharma with two marketed complement inhibitors: SYFOVRE for geographic atrophy ($586.9M US net revenue 2025) and EMPAVELI for PNH/C3G/IC-MPGN ($102.4M US net revenue). Ex-U.S. commercialization of EMPAVELI is handled by Sobi. In March 2026, Apellis announced a merger agreement with Biogen at $41.00/share plus a CVR.